AU2005271814B2 - Compositions and formulations of decitabine polymorphs and methods of use thereof - Google Patents

Compositions and formulations of decitabine polymorphs and methods of use thereof Download PDF

Info

Publication number
AU2005271814B2
AU2005271814B2 AU2005271814A AU2005271814A AU2005271814B2 AU 2005271814 B2 AU2005271814 B2 AU 2005271814B2 AU 2005271814 A AU2005271814 A AU 2005271814A AU 2005271814 A AU2005271814 A AU 2005271814A AU 2005271814 B2 AU2005271814 B2 AU 2005271814B2
Authority
AU
Australia
Prior art keywords
decitabine
polymorph
tumor
endotherm
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005271814A
Other languages
English (en)
Other versions
AU2005271814A1 (en
Inventor
Rajashree Joshi-Hangal
Sanjeev Redkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35600347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005271814(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of AU2005271814A1 publication Critical patent/AU2005271814A1/en
Application granted granted Critical
Publication of AU2005271814B2 publication Critical patent/AU2005271814B2/en
Priority to AU2011200539A priority Critical patent/AU2011200539A1/en
Priority to AU2011200540A priority patent/AU2011200540A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2005271814A 2004-07-13 2005-07-12 Compositions and formulations of decitabine polymorphs and methods of use thereof Ceased AU2005271814B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2011200539A AU2011200539A1 (en) 2004-07-13 2011-02-09 Compositions and formulations of decitabine polymorphs and methods of use thereof
AU2011200540A AU2011200540A1 (en) 2004-07-13 2011-02-09 Compositions and formulations of decitabine polymorphs and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/890,828 2004-07-13
US10/890,828 US20060014949A1 (en) 2004-07-13 2004-07-13 Compositions and formulations of decitabine polymorphs and methods of use thereof
PCT/US2005/024676 WO2006017278A1 (en) 2004-07-13 2005-07-12 Compositions and formulations of decitabine polymorphs and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2011200540A Division AU2011200540A1 (en) 2004-07-13 2011-02-09 Compositions and formulations of decitabine polymorphs and methods of use thereof
AU2011200539A Division AU2011200539A1 (en) 2004-07-13 2011-02-09 Compositions and formulations of decitabine polymorphs and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2005271814A1 AU2005271814A1 (en) 2006-02-16
AU2005271814B2 true AU2005271814B2 (en) 2010-11-11

Family

ID=35600347

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2005271814A Ceased AU2005271814B2 (en) 2004-07-13 2005-07-12 Compositions and formulations of decitabine polymorphs and methods of use thereof
AU2011200539A Abandoned AU2011200539A1 (en) 2004-07-13 2011-02-09 Compositions and formulations of decitabine polymorphs and methods of use thereof
AU2011200540A Abandoned AU2011200540A1 (en) 2004-07-13 2011-02-09 Compositions and formulations of decitabine polymorphs and methods of use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2011200539A Abandoned AU2011200539A1 (en) 2004-07-13 2011-02-09 Compositions and formulations of decitabine polymorphs and methods of use thereof
AU2011200540A Abandoned AU2011200540A1 (en) 2004-07-13 2011-02-09 Compositions and formulations of decitabine polymorphs and methods of use thereof

Country Status (7)

Country Link
US (1) US20060014949A1 (https=)
EP (1) EP1765076A4 (https=)
JP (1) JP5159307B2 (https=)
CN (1) CN101014246A (https=)
AU (3) AU2005271814B2 (https=)
CA (1) CA2573332A1 (https=)
WO (1) WO2006017278A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
JP5687687B2 (ja) 2009-04-06 2015-03-18 大塚製薬株式会社 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
WO2010129211A2 (en) * 2009-04-27 2010-11-11 Dr. Reddy's Laboratories Ltd. Preparation of decitabine
CN101781347B (zh) * 2009-12-21 2012-09-12 南京卡文迪许生物工程技术有限公司 地西他滨多晶型物和药用组合物
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
EP2766041B1 (en) 2011-10-12 2018-12-05 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
US20140094598A1 (en) 2012-10-01 2014-04-03 Johnson Matthey Public Limited Company Method for the purification of decitabine
CN103191144B (zh) * 2013-04-25 2014-06-18 李伟丽 一种治疗癌症的药物组合物及应用
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
WO2019025256A1 (en) 2017-08-01 2019-02-07 Bayer Aktiengesellschaft COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS
KR20200035438A (ko) 2017-08-03 2020-04-03 오쓰까 세이야꾸 가부시키가이샤 약물 화합물 및 이의 정제 방법
JP7089603B2 (ja) 2018-06-11 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼疾患を治療するための脱メチル化
PH12022552250A1 (en) 2020-02-25 2023-11-13 Otsuka Pharma Co Ltd Combination decitabine and cedazuridine solid oral dosage forms
EP4138843A4 (en) 2020-04-23 2024-07-10 Southern Research Institute COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF
WO2022020747A1 (en) * 2020-07-23 2022-01-27 Southern Research Institute Polymorophs of 5-aza-4'-thio-2-deoxycytidine
CN119943194A (zh) * 2023-11-03 2025-05-06 中国石油天然气股份有限公司 一种分子筛晶胞参数确定方法和装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (https=) * 1963-12-22
CH527207A (de) * 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
JPS5213741B2 (https=) * 1972-05-22 1977-04-16
JPS5527077A (en) * 1978-08-16 1980-02-26 Shin Meiwa Ind Co Ltd Solids scraper for sludge dehydrator
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
KR101150250B1 (ko) * 2001-03-01 2012-06-12 아보트 래버러토리즈 시스-ｆｔｃ의 다형 및 기타 결정형
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract

Also Published As

Publication number Publication date
AU2011200540A8 (en) 2011-03-10
WO2006017278A1 (en) 2006-02-16
AU2011200540A1 (en) 2011-03-03
AU2011200539A1 (en) 2011-03-03
JP2008506690A (ja) 2008-03-06
EP1765076A1 (en) 2007-03-28
JP5159307B2 (ja) 2013-03-06
EP1765076A4 (en) 2009-04-22
US20060014949A1 (en) 2006-01-19
CN101014246A (zh) 2007-08-08
CA2573332A1 (en) 2006-02-16
AU2005271814A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
AU2011200539A1 (en) Compositions and formulations of decitabine polymorphs and methods of use thereof
US6696458B2 (en) Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
US20100062992A1 (en) Salts of 5-Azacytidine
US20060069060A1 (en) Salts of decitabine
US7858594B2 (en) Crystalline and amorphous forms of beta-L-2′-deoxythymidine
AU2005289513B2 (en) Salts of decitabine
HK1184163A (en) Amorphous form of beta- l-2'-deoxythymidine
AU2012202255A1 (en) Salts of 5-azacytidine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired